Abstract 1600P
Background
Sarcopenia is a disorder that causes muscle mass and strength loss, which can result in diminished mobility and functional limits. Depression and a bad assessment of one's own health are common results among cancer patients. As a result, this study aimed to look at the association between sarcopenia, depression, and health perception.
Methods
Cancer patients were the subject of a retrospective study from January to April 2023. The study included 150 patients who had different forms of a verified cancer diagnosis. These individuals were admitted to Mayo Hospital's Palliative Care Cancer Department. The presence of depressive symptoms was assessed using the Patient Health Questionnaire (PHQ-9). SARC-F was used to measure all the five dimensions of sarcopenia. To examine self-perceived health, a self-report questionnaire was used. The relationships between sarcopenia, depression, and health perception were investigated using correlation analysis.
Results
We observed a significant and positive association between depression and the dimensions of sarcopenia. Specifically, we found a positive correlation between depression and SARC1=Strength (r = 0.378, p<0.01), SARC2=Assistance in walking (r = 0.390, p<0.01), SARC3=Rise from a chair (r = 0.488, p<0.01), and SARC4=Climb stairs (r = 0.392, p<0.01). However, we found a positive but insignificant relationship between depression and SARC5=Falls (r = 0.150, p>0.05). In addition, we discovered that patients' perception of poor health was correlated with depression (r = -0.391, p<0.01), SARC2=Assistance in walking (r = -0.235, p<0.01), SARC3=Rise from a chair (r = -0.259, p<0.01), and SARC4=Climb stairs (r = -0.277, p<0.01). However, we did not find a significant relationship between health perception and two dimensions of sarcopenia (i.e., SARC1=Strength and SARC5=Falls).
Conclusions
Sarcopenia adversely affects the physical and mental health of cancer patients. They feel depressed and perceive their health as bad which imparts a negative impact on the outcome of these patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2018P - Novel nomogram based on the expression of DLL3 and PD-L1 for predicting the prognosis of small cell lung cancer patients
Presenter: Jun Zhao
Session: Poster session 05
2019P - Analysis of lung immune prognostic index (LIPI) score in a small cell lung cancer carcinoma (SCLC) cohort, supporting its prognostic use and investigating its predictive potential
Presenter: Mónica Esteban García
Session: Poster session 05
2020P - Circulating micro RNAs (cmiRNAs) as treatment outcome predictors in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab plus carboplatin and etoposide (ACE): CATS/ML43257 study
Presenter: Giulia Pasello
Session: Poster session 05
2021P - Cell-free (cf) DNA as predictive biomarker (B) of treatment outcome in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab, carboplatin and etoposide (ACE): CATS/ML43257 study
Presenter: Giulia Pasello
Session: Poster session 05
2022P - ALBA project: Prognostic impact of laterality in small cell lung cancer
Presenter: Lorenza Landi
Session: Poster session 05
2024P - Supportive measures to control myelosuppression and costs for patients with SCLC with lurbinectedin, CAV or topotecan with or without trilaciclib: A review on the basis of clinical trials
Presenter: Manuel Dómine
Session: Poster session 05
2025P - Stratified control study of neuroendocrine differentiation and potential clinicopathologic markers
Presenter: Li Liu
Session: Poster session 05
2026P - Small cell lung cancer (SCLC) in the KBP-2020-CPHG cohort and comparison with 2000 and 2010
Presenter: Lionel Falchero
Session: Poster session 05
2027P - Immune checkpoint inhibitors in the treatment of small cell lung cancer: A systematic review and meta-analysis
Presenter: Patsy Lee
Session: Poster session 05